Dapagliflozin → Epilepsy

Original Indication

Antidiabetic (Type 2 Diabetes), Heart Failure, Chronic Kidney Disease

Proposed New Indication

Dapagliflozin shows potential as an anticonvulsant by targeting neuroinflammatory pathways, offering a new repurposing opportunity for epilepsy treatment.

Proposed Mechanism

Targets: MAPK_ERK1/2, TLR4, NF-kB, GABA/GAD1

Dapagliflozin significantly ameliorated MES-induced convulsions by inhibiting the protein expression of p-ERK1/2, p-TLR4, and p65 subunit of NF-κB, which are involved in the neuroinflammatory cascade. It also improved GABA/GAD1 ratios.

Evidence

Level: In vivo (mice model), Network Pharmacology

Source: Dhureja, M., Munshi, A., & Kumar, P. (2025). Targeting neuroinflammatory pathways in epilepsy: a combined network-pharmacology and in vivo study of dapagliflozin and ticagrelor. Inflammopharmacology, 33(12), 7549-7567.

Reference: PubMed 41249612

Repurposing Score